Arbele is forging ahead with bispecific T-cell engager (TCE) and antibody-drug conjugate (ADC) approaches to drug its patented Cadherin 17 (CDH17) target, which was previously half-forgotten by the industry but is now back in the limelight.
Key Takeaways
- Arbele is moving towards a pivotal Phase II trial with cabotamig (ARB202), a potentially first-in-class CDH17 x CD3 TCE for the treatment of gastrointestinal cancers.
- The asset entered the clinic in 2022 and remains one of the most advanced CDH17-targeting agents worldwide
Arbele’s refuelled drive toward a pivotal Phase II clinical trial with cabotamig (ARB202), its potentially first-in-class CDH17 x CD3 TCE for the treatment of gastrointestinal (GI) cancers, is expected to help the firm hold onto a years-long head start advantage over an increasing